Whole Tumor Cell Vaccine Adjuvants: Comparing IL-12 to IL-2 and IL-15.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Iranian journal of immunology : IJI

• Publication date

  2016-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 27671507
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ibrutinib-A double-edge sword in cancer and autoimmune disorders

  2016cited by this paper
• Targeting Receptor Tyrosine Kinases Using Monoclonal Antibodies: The Most Specific Tools for Targeted-Based Cancer Therapy.

  2016cited by this paper
• Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances

  2016cited by this paper
• The PI3K/AKT/mTOR pathway is involved in direct apoptosis of CLL cells induced by ROR1 monoclonal antibodies

  2015cited by this paper
• Novel and emerging targeted-based cancer therapy agents and methods

  2015cited by this paper
• The skewed balance between Tregs and Th17 in chronic lymphocytic leukemia.

  2015cited by this paper
• Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies

  2014cited by this paper
• Upregulation of CD200 is associated with Foxp3+ regulatory T cell expansion and disease progression in acute myeloid leukemia

  2013cited by this paper
• Augmenting the Expression of NKp44 Molecule and the Natural Killer Activity in Peripheral Blood Mononuclear Cells from Patients with Malignant Colorectal Carcinoma

  2013cited by this paper
• Xenogeneic Human p53 DNA Vaccination by Electroporation Breaks Immune Tolerance to Control Murine Tumors Expressing Mouse p53

  2013cited by this paper
• Blocking retinoic acid receptor-α enhances the efficacy of a dendritic cell vaccine against tumours by suppressing the induction of regulatory T cells

  2013cited by this paper
• Collapse of the tumor stroma is triggered by IL-12 induction of Fas.

  2013cited by this paper
• CTLA-4 blockade in tumor models: an overview of preclinical and translational research.

  2013cited by this paper
• Abstract 3141: High-content live-cell imaging analysis of therapeutic monoclonal antibody binding and potency across 240 genomically defined cancer cell lines.

  2013cited by this paper
• Combination of SLC administration and Tregs depletion is an attractive strategy for targeting hepatocellular carcinoma

  2013cited by this paper
• The Role of IL-15 in Human Cancer: Friend or Foe?

  2013cited by this paper
• Localized interleukin-12 delivery for immunotherapy of solid tumours

  2013cited by this paper
• Enhanced antitumor response mediated by the codelivery of paclitaxel and adenoviral vector expressing IL-12.

  2013cited by this paper
• Peripheral Helper Lymphocytes Produce Interleukin 12 in Cancer Patients

  2013cited by this paper
• Antiangiogenic therapy promoted metastasis of hepatocellular carcinoma by suppressing host-derived interleukin-12b in mouse models

  2013cited by this paper
• The impact of intraoperative vaccination with IL-12 modified autologous tumor cells in the Lewis lung carcinoma mouse model

  2012cited by this paper
• Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.

  2012cited by this paper
• Antibody specification beyond the target: claiming a later-generation therapeutic antibody by its target epitope

  2012cited by this paper
• CD4+CD25+ Treg derived from hepatocellular carcinoma mice inhibits tumor immunity.

  2012cited by this paper
• Local Delivery of lnterleukin-12 Using T Cells Targeting VEGF Receptor-2 Eradicates Multiple Vascularized Tumors in Mice

  2012cited by this paper
• An afucosylated anti-CD20 monoclonal antibody with greater antibody-dependent cellular cytotoxicity and B-cell depletion and lower complement-dependent cytotoxicity than rituximab.

  2012cited by this paper
• Evasion of tumours from the control of the immune system: consequences of brief encounters

  2012cited by this paper
• Vaccination with dendritic cells loaded with tumor apoptotic bodies (Apo-DC) in patients with chronic lymphocytic leukemia: effects of various adjuvants and definition of immune response criteria

  2012cited by this paper
• IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression.

  2011cited by this paper
• IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors.

  2011cited by this paper
• In vitro modulation of natural killer activity of human peripheral blood mononuclear cells against prostate tumor cell line

  2011cited by this paper
• Adjuvants for Enhancing the Immunogenicity of Whole Tumor Cell Vaccines

  2011cited by this paper
• Immune responses regulation following antitumor dendritic cell-based prophylactic, concurrent, and therapeutic vaccination

  2011cited by this paper
• Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate

  2011cited by this paper
• Combination of IL-21 and IL-15 enhances tumour-specific cytotoxicity and cytokine production of TCR-transduced primary T cells

  2010cited by this paper
• Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts.

  2010cited by this paper
• Natural-killer cell amplification for adoptive leukemia relapse immunotherapy: comparison of three cytokines, IL-2, IL-15, or IL-7 and impact on NKG2D, KIR2DL1, and KIR2DL2 expression.

  2010cited by this paper
• Expression of interleukin 15 in primary adult acute lymphoblastic leukemia

  2010cited by this paper
• Cancer esearch oenvironment and Immunology or-Specific CD 8 + T Cells Expressing Interleukin-12 R dicate Established Cancers in Lymphodepleted Hosts

  2010cited by this paper
• IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice.

  2010cited by this paper
• TGFbeta, a potent regulator of tumor microenvironment and host immune response, implication for therapy.

  2010cited by this paper
• Simultaneous Blockade of Multiple Immune System Inhibitory Checkpoints Enhances Antitumor Activity Mediated by Interleukin-15 in a Murine Metastatic Colon Carcinoma Model

  2010cited by this paper
• Irradiation and IL-15 promote loss of CD8 T-cell tolerance in response to lymphopenia.

  2010cited by this paper
• Suppressive Influences in the Immune Response to Cancer

  2009cited by this paper
• On immunotherapies and cancer vaccination protocols: a mathematical modelling approach.

  2009cited by this paper
• IL-15 Regulates Both Quantitative and Qualitative Features of the Memory CD8 T Cell Pool

  2009cited by this paper
• Safety and immunologic effects of IL-15 administration in nonhuman primates.

  2009cited by this paper
• Interleukin-12 receptor beta2: from cytokine receptor to gatekeeper gene in human B-cell malignancies.

  2009cited by this paper
• Radiofrequency thermal ablation of breast tumors combined with intralesional administration of IL-7 and IL-15 augments anti-tumor immune responses and inhibits tumor development and metastasis

  2009cited by this paper
• IL‐12 immunotherapy of murine leukaemia: comparison of systemic versus gene modified cell therapy

  2009cited by this paper
• Human renal cancer cells express a novel membrane-bound interleukin-15 that induces, in response to the soluble interleukin-15 receptor alpha chain, epithelial-to-mesenchymal transition.

  2009cited by this paper
• Ex vivo expansion of tumor specific lymphocytes with IL-15 and IL-21 for adoptive immunotherapy in melanoma.

  2009cited by this paper
• Hypoxia increases tumor cell shedding of MHC class I chain-related molecule: role of nitric oxide.

  2008cited by this paper
• Interleukin 15 augments antitumor activity of cytokine gene-modified melanoma cell vaccines in a murine model.

  2008cited by this paper
• An effective vaccine against colon cancer in mice: use of recombinant adenovirus interleukin-12 transduced dendritic cells.

  2008cited by this paper
• The effect of poly(D,L-lactide-co-glycolide) microparticles with polyelectrolyte self-assembled multilayer surfaces on the cross-presentation of exogenous antigens.

  2008cited by this paper
• Interleukin‐2 in the development and control of inflammatory disease

  2008cited by this paper
• In-vitro effects of Mycobacterium bovis BCG-lysate and its derived heat shock proteins on cytokines secretion by blood mononuclear cells of rheumatoid arthritis patients in comparison with healthy controls.

  2008cited by this paper
• Injection of IL-12 gene-transduced dendritic cells into mouse liver tumor lesions activates both innate and acquired immunity

  2007cited by this paper
• Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy

  2007cited by this paper
• Generation of DC-based vaccine for therapy of B-CLL patients. Comparison of two methods for enriching monocytic precursors.

  2006cited by this paper
• Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer.

  2006cited by this paper
• The biology and treatment of chronic lymphocytic leukemia.

  2006cited by this paper
• Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.

  2005cited by this paper
• Fueling regulation: IL-2 keeps CD4+ Treg cells fit

  2005cited by this paper
• Development and function of agonist-induced CD25+Foxp3+ regulatory T cells in the absence of interleukin 2 signaling

  2005cited by this paper
• Biology and treatment of chronic lymphocytic leukemia.

  2005cited by this paper
• Cellular mechanisms governing cross-presentation of exogenous antigens

  2004cited by this paper
• Apoptotic tumor cells are superior to tumor cell lysate, and tumor cell RNA in induction of autologous T cell response in B-CLL

  2004cited by this paper
• Reverse Signaling through Membrane-bound Interleukin-15*

  2004cited by this paper
• Rapid, in vivo, evaluation of antiangiogenic and antineoplastic gene products by nonviral transfection of tumor cells

  2004cited by this paper
• Regulation of interleukin‐12 gene expression and its anti‐tumor activities by prostaglandin E2 derived from mammary carcinomas

  2004cited by this paper
• T-cell anergy.

  2004cited by this paper
• Complete tumour regressions induced by vaccination with IL-12 gene-transduced tumour cells in combination with IL-15 in a melanoma model in mice

  2004cited by this paper
• Mechanisms and functional significance of tumour-induced dendritic-cell defects

  2004cited by this paper
• Natural mechanisms protecting against cancer.

  2003cited by this paper
• Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control.

  2003cited by this paper
• Interleukin 12-based immunotherapy improves the antitumor effectiveness of a low-dose 5-Aza-2'-deoxycitidine treatment in L1210 leukemia and B16F10 melanoma models in mice.

  2003cited by this paper
• IL-15 induces antigen-independent expansion and differentiation of human naive CD8+ T cells in vitro.

  2003cited by this paper
• Chimeric Co-stimulatory Molecules That Selectively Act through CD28 or CTLA-4 on Human T Cells*

  2002cited by this paper
• Cytokines as a link between innate and adaptive antitumor immunity.

  2002cited by this paper
• Interleukin-12 in anti-tumor immunity and immunotherapy.

  2002cited by this paper
• IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells.

  2002cited by this paper
• Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy.

  2001cited by this paper
• IL-12 Inhibition of Endothelial Cell Functions and Angiogenesis Depends on Lymphocyte-Endothelial Cell Cross-Talk1

  2001cited by this paper
• Interleukin 15: biology and relevance to human disease.

  2001cited by this paper
• Inhibition of mammary carcinogenesis by systemic interleukin 12 or p185neu DNA vaccination in Her-2/neu transgenic BALB/c mice.

  2001cited by this paper
• Induction of Th1 response by dendritic cells pulsed with autologous melanoma apoptotic bodies.

  2000cited by this paper
• Cytokines in cancer therapy.

  2000cited by this paper
• IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice.

  2000cited by this paper
• Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer.

  2000cited by this paper
• Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12.

  2000cited by this paper
• Identification of IFN-gamma-producing cells in IL-12/IL-18-treated mice.

  1999cited by this paper
• Vaccines with interleukin-12-transduced acute myeloid leukemia cells elicit very potent therapeutic and long-lasting protective immunity.

  1999cited by this paper
• Hypoxia-mediated apoptosis from angiogenesis inhibition underlies tumor control by recombinant interleukin 12.

  1999cited by this paper
• Identification of IFN-γ-Producing Cells in IL-12/IL-18-Treated Mice

  1999cited by this paper
• Recruitment of hepatic NK cells by IL-12 is dependent on IFN-gamma and VCAM-1 and is rapidly down-regulated by a mechanism involving T cells and expression of Fas.

  1998cited by this paper
• HLA and cancer: from research to clinical impact.

  1998cited by this paper
• IgG2a induced by interleukin (IL) 12-producing tumor cell vaccines but not IgG1 induced by IL-4 vaccine is associated with the eradication of experimental metastases.

  1998cited by this paper
• Cytokines, tumour-cell death and immunogenicity: a question of choice.

  1997cited by this paper

• Tumor Vaccines for Malignant Melanoma: Progress, Challenges, and Future Directions

  2025cites this paper
• Hesperidin nanoparticles for prostate cancer therapy: preparation, characterization and cytotoxic activity

  2024cites this paper
• Augmented interferon regulatory factor 7 axis in whole tumor cell vaccines prevents tumor recurrence by inducing interferon gamma-secreting B cells

  2023cites this paper
• Leptin/lipopolysaccharide-treated dendritic cell vaccine improved cellular immune responses in an animal model of breast cancer

  2023cites this paper
• Cytokines and their role as immunotherapeutics and vaccine Adjuvants: The emerging concepts.

  2023cites this paper
• Development of anti-rituximab antibodies in rituximab-treated patients: Related parameters & consequences

  2022cites this paper
• Cimetidine and Ibuprofen Modulate T Cell Responses in a Mouse Model of Breast Cancer

  2022cites this paper
• SARS-CoV-2 Infection: A Possible Risk Factor for Incidence and Recurrence of Cancers

  2022cites this paper
• Cancer immunotherapy: A comprehensive appraisal of its modes of application.

  2021influential citation
• Allogeneic tumor cell line-based vaccines: A good alternative to autologous and cancer stem cell vaccines in colorectal cancer

  2021cites this paper
• Recent Advances in Understanding the Mechanisms of Elemene in Reversing Drug Resistance in Tumor Cells: A Review

  2021cites this paper
• Pathophysiological Roles of Histamine Receptors in Cancer Progression: Implications and Perspectives as Potential Molecular Targets

  2021cites this paper
• Zingerone improves the immune responses in an animal model of breast cancer

  2021cites this paper
• The construction of a lymphoma cell-based, DC-targeted vaccine, and its application in lymphoma prevention and cure

  2020cites this paper
• Genetic and molecular determinants of prostate cancer among Iranian patients: An update

  2020cites this paper
• Role of Apelin/APJ axis in cancer development and progression.

  2020cites this paper
• Association of elevated interleukin-33 serum levels with tumorstages in patients with prostate cancer

  2019cites this paper
• Serum concentration of interleukin‐35 and its association with tumor stages and FOXP3 gene polymorphism in patients with prostate cancer

  2019cites this paper
• Irradiated Bladder Cancer Cells Expressing both GM-CSF and IL-21 versus Either GM-CSF or IL-21 Alone as Tumor Vaccine in a Mouse Xenograft Model

  2019cites this paper
• Overexpression of Semaphorin-3 A and Semaphorin-4 D in the Peripheral Blood from Newly Diagnosed Patients with Chronic Lymphocytic Leukemia

  2019cites this paper
• Gastrodin, a traditional Chinese medicine monomer compound, can be used as adjuvant to enhance the immunogenicity of melanoma vaccines.

  2019cites this paper
• تهیه و ارزیابی ویژگیهای نانوذرات پلیلاکتیک-کو-گلیکولیک اسید حامل عصاره سلول توموری و Poly-IC و بررسی اثرات ضد توموری آن در مدل موشی سرطان پستان

  2019cites this paper
• Whole Tumor Cell Vaccine for Cancer

  2019cites this paper
• Overexpression of Semaphorin-3A and Semaphorin-4D in the Peripheral Blood from Newly Diagnosed Patients with Chronic Lymphocytic Leukemia

  2019cites this paper
• Immunomodulatory properties of cimetidine: Its therapeutic potentials for treatment of immune‐related diseases

  2019cites this paper
• Thoracic injection of low-dose interleukin-2 as an adjuvant therapy improves the control of the malignant pleural effusions: a systematic review and meta-analysis base on Chinese patients

  2018cites this paper
• Overexpression of Regulatory T Cell-Related Markers (FOXP3, CTLA-4 and GITR) by Peripheral Blood Mononuclear Cells from Patients with Breast Cancer

  2018cites this paper
• Kefir: a powerful probiotics with anticancer properties

  2017cites this paper